From helping companies do more with their patents, to improving diagnostics for patients in critical care – we meet two 90 Day Finns bringing technology innovation from Tel Aviv and Boston.
William Carbone is CEO and co-founder of The Adjacent Possible, an R&D company that helps organizations identify licensing opportunities for their intellectual property. Carbone is a former IBM executive and an expert in promoting technology innovation around quantum computing, blockchain, AI and IoT. He has published more than 10 scientific papers and given some 40 keynotes at international conferences.
Carbone together with the other founders, Vlad Lichtenthal and Nick Sgobba, established The Adjacent Possible on the premise that some 80% of granted patents are never used. The business partners came up with a methodology, itself patent protected, that companies can tap into to discover opportunities for the unrealized value of their intellectual property.
“Our business model requires highly-efficient patent law infrastructure and related capabilities, a global mindset, a diverse group of technology-driven companies, and a solid base of venture capital. We find everything we need and more in Finland,” he says.
An Italian citizen who lives in Tel Aviv – another city with a thriving tech scene – Carbone first learned of the 90 Day Finn program through a LinkedIn post from Helsinki Business Hub. Upon being selected, he established The Adjacent Possible as a Finnish company and is now working with local and international businesses to identify and realize opportunities for licensing their patents.
“We come to Helsinki to learn, connect and contribute,” says William. “Finland is a technology-driven country with impressive resources, capabilities and innovation ecosystems. But there is still significant potential for sustainable growth and development of these attributes.”
Automated diagnostics for critical care patients
US-citizen Jeff Valk is another 90 Day Finn focused on technology innovation. He’s co-founder and CEO of Boston-based Admetsys, a medical-technology company that has developed the first fully-automated glucose control and continuous blood diagnostics system for hospital care.
“Nearly 80% of people in critical care have dysglycemia – blood glucose that is too high or too low – due to their metabolism becoming destabilized,” says Jeff. “We’ve built a sensor that connects directly to the patient’s intravenous line to model their metabolism in real time and infuse both insulin and dextrose as needed.”
Jeff previously lived in Denmark and has used his connections there to establish several clinical collaborations in Scandinavia. Now he’s hoping to engage with the healthcare community in Finland too. He also wants to learn more about the country’s business culture and hiring policies as Admetsys looks to establish a European base.
“Everywhere in the world there are economic pressures on healthcare. By coming to Helsinki as part of this program, I want to understand the specific challenges that Finland is facing,” says Jeff. “There is a consensus in Finland that healthcare is socially important. The Finnish community also takes pride in being technologically progressive. Together these two dynamics give me hope that there will be sympathetic opinions and a lot of thoughtfulness as to what is desirable and possible through the kind of technology we’re offering. We would love to end up with leading hospital customers in Finland if our solution turns out to be compatible,” he says.
Writer: Andrew Flowers